Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3

Abstract Background: The secosteroid 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) actsthrough the vitamin D receptor (VDR) to elicit many activities that make it a promising drug candidate for the treatment of a number of diseases, including cancer and psoriasis. Clinical use of 1,25(OH) 2 D 3 has been limited by hypercalcemia elicited by pharmacologically effective doses. We hypothesized that structurally distinct, nonsecosteroidal mimics of 1,25(OH) 2 D 3 might have different activity profiles from vitamin D analogs, and set out to discover such compounds by screening small-molecule libraries. Results: A bis -phenyl derivative was found to activate VDR in a transactivationscreening assay. Additional related compounds were synthesized that mimicked various activities of 1,25(OH) 2 D 3 , including growth inhibition of cancer cells and keratinocytes, as well as induction of leukemic cell differentiation. In contrast to 1,25(OH) 2 D 3 , these synthetic compounds did not demonstrate appreciable binding to serum vitamin D binding protein, a property that is correlated with fewer calcium effects in vivo . Two mimics tested in mice showed greater induction of a VDR target gene with less elevation of serum calcium than 1,25(OH) 2 D 3 . Conclusions: These novel VDR modulators may have potential as therapeutics for cancer, leukemia and psoriasis with less calcium mobilization side effects than are associated with secosteroidal 1,25(OH) 2 D 3 analogs.